Michael M. Morrissey, Ph.D., is a distinguished figure in the biotechnology industry, currently serving as the President and Chief Executive Officer at Exelixis, Inc. Dr. Morrissey joined Exelixis in 2006 and has been instrumental in steering the company towards significant growth and innovation. Prior to his role at Exelixis, he held various leadership positions in the pharmaceutical and biotechnology sectors, including roles at ALZA Corporation and Berlex Biosciences. His extensive experience in drug discovery and development has been pivotal in shaping Exelixis' strategic direction. Under Dr. Morrissey's leadership, Exelixis has achieved notable milestones, particularly with the development and commercialization of CABOMETYX® (cabozantinib), a targeted cancer therapy that has transformed the treatment landscape for patients with advanced renal cell carcinoma and other cancers. His strategic vision has also led to the expansion of Exelixis' pipeline, with multiple ongoing clinical trials exploring new indications for cabozantinib and other novel compounds. Dr. Morrissey's commitment to advancing oncology research has not only solidified Exelixis' position as a leader in cancer therapy but also brought hope to countless patients worldwide. In his role as President and CEO, Dr. Morrissey oversees all aspects of Exelixis' operations, from research and development to commercialization and corporate strategy. He is known for fostering a collaborative and innovative work environment, encouraging his team to push the boundaries of science to deliver life-changing therapies. Dr. Morrissey's leadership is characterized by his deep scientific knowledge, strategic foresight, and dedication to improving patient outcomes, making him a respected figure in the biotech community.